Loading...
XNYSBIO
Market cap9.64bUSD
Jan 07, Last price  
343.99USD
1D
0.15%
1Q
1.59%
Jan 2017
88.72%
Name

Bio Rad Laboratories Inc

Chart & Performance

D1W1MN
XNYS:BIO chart
P/E
P/S
3.61
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
-0.68%
Rev. gr., 5y
3.13%
Revenues
2.67b
-4.67%
1,090,012,0001,180,985,0001,273,930,0001,461,052,0001,764,365,0001,784,244,0001,927,118,0002,073,529,0002,069,235,0002,132,694,0002,175,044,0002,019,441,0002,068,172,0002,160,153,0002,290,109,0002,311,659,0002,545,626,0002,922,545,0002,802,249,0002,671,262,000
Net income
-637m
L-82.43%
68,242,00081,553,000103,263,00092,994,00089,510,000144,620,000185,490,000178,223,000169,234,00077,790,00088,845,000113,093,00028,125,000114,740,000360,996,0001,758,675,0003,814,229,0004,254,257,000-3,627,535,000-637,324,000
CFO
375m
+92.83%
123,093,000108,284,000118,229,000191,580,000191,371,000325,074,000225,909,000259,816,000278,898,000175,476,000273,312,000186,210,000216,433,000103,885,000285,494,000457,897,000575,328,000656,521,000194,447,000374,943,000
Earnings
Feb 13, 2025

Profile

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
IPO date
Mar 17, 1980
Employees
8,200
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,671,262
-4.67%
2,802,249
-4.12%
Cost of revenue
1,466,843
1,491,808
Unusual Expense (Income)
NOPBT
1,204,419
1,310,441
NOPBT Margin
45.09%
46.76%
Operating Taxes
(212,780)
(1,076,738)
Tax Rate
NOPAT
1,417,199
2,387,179
Net income
(637,324)
-82.43%
(3,627,535)
-185.27%
Dividends
Dividend yield
Proceeds from repurchase of equity
(428,728)
69,370,220
BB yield
4.55%
-553.89%
Debt
Debt current
40,379
465
Long-term debt
1,560,787
1,387,649
Deferred revenue
9,648
1,770,481,000
Other long-term liabilities
204,713
(1,770,131,491)
Net debt
(7,702,546)
(9,239,010)
Cash flow
Cash from operating activities
374,943
194,447
CAPEX
(156,680)
(114,157)
Cash from investing activities
20,208
(1,207,593)
Cash from financing activities
(425,647)
973,576
FCF
1,172,000
2,043,025
Balance
Cash
1,607,142
1,796,232
Long term investments
7,696,570
8,830,892
Excess cash
9,170,149
10,487,012
Stockholders' equity
8,924,594
9,431,384
Invested Capital
1,416,561
1,699,130
ROIC
90.97%
202.53%
ROCE
10.19%
10.16%
EV
Common stock shares outstanding
29,209
29,785
Price
322.89
-23.21%
420.49
-44.35%
Market cap
9,431,294
-24.70%
12,524,295
-45.13%
EV
1,728,748
3,285,285
EBITDA
1,204,419
1,447,737
EV/EBITDA
1.44
2.27
Interest
49,439
38,114
Interest/NOPBT
4.10%
2.91%